open access

Vol 15, No 5 (2019)
REVIEW ARTICLES
Published online: 2019-10-29
Get Citation

Clinical practice of renal cell carcinoma treatment with nivolumab

Paweł M Potocki, Piotr J Wysocki
DOI: 10.5603/OCP.2019.0002
·
Oncol Clin Pract 2019;15(5):237-245.

open access

Vol 15, No 5 (2019)
REVIEW ARTICLES
Published online: 2019-10-29

Abstract

Nivolumab alike other immune checkpoint inhibitors has been intensively developed during the last decade. Kidney cancer is among the neoplasm in treatment of which we have accumulated the most experience regarding nivolumab. As improves our understanding of the mechanisms underlying specific cellular immune response, thus improves our understanding of the place the nivolumab holds among other therapeutic options. Recent years brought development of innovative immunotherapy combinations as a method for improving immunotherapy efficacy. This review aims at providing practicing oncologists with key aspects of renal cell carcinoma treatment with nivolumab.

Abstract

Nivolumab alike other immune checkpoint inhibitors has been intensively developed during the last decade. Kidney cancer is among the neoplasm in treatment of which we have accumulated the most experience regarding nivolumab. As improves our understanding of the mechanisms underlying specific cellular immune response, thus improves our understanding of the place the nivolumab holds among other therapeutic options. Recent years brought development of innovative immunotherapy combinations as a method for improving immunotherapy efficacy. This review aims at providing practicing oncologists with key aspects of renal cell carcinoma treatment with nivolumab.

Get Citation

Keywords

kidney cancer; renal cell carcinoma; nivolumab, anti-PD-1, immunotherapy; checkpoint inhibitor

About this article
Title

Clinical practice of renal cell carcinoma treatment with nivolumab

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 5 (2019)

Pages

237-245

Published online

2019-10-29

DOI

10.5603/OCP.2019.0002

Bibliographic record

Oncol Clin Pract 2019;15(5):237-245.

Keywords

kidney cancer
renal cell carcinoma
nivolumab
anti-PD-1
immunotherapy
checkpoint inhibitor

Authors

Paweł M Potocki
Piotr J Wysocki

References (43)
  1. Hoption Cann SA, van Netten JP, van Netten C, et al. Spontaneous regression: a hidden treasure buried in time. Med Hypotheses. 2002; 58(2): 115–119.
  2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
  3. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19): 3167–3175.
  4. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21(3): 309–322.
  5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646–674.
  6. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1): 1–10.
  7. Iwai Y, Terawaki S, Ikegawa M, et al. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med. 2003; 198(1): 39–50.
  8. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4): 450–461.
  9. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457): 214–218.
  10. Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017; 377(25): 2500–2501.
  11. Garg AD, Romano E, Rufo N, et al. Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ. 2016; 23(6): 938–951.
  12. Schmidt C. The benefits of immunotherapy combinations. Nature. 2017; 552(7685): S67–S69.
  13. Fiorica F, Belluomini L, Stefanelli A, et al. Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination. Am J Clin Oncol. 2018 [Epub ahead of print].
  14. Ansari J, Farrag A, Ali A, et al. Concurrent nivolumab and radiotherapy to improve outcomes for patients with metastatic lung and renal cancers. Journal of Clinical Oncology. 2018; 36(15_suppl): e15078–e15078.
  15. Liu Y, Dong Y, Kong Li, et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018; 11(1): 104.
  16. Alloatti A, Kotsias F, Magalhaes JG, et al. Dendritic cell maturation and cross-presentation: timing matters! Immunol Rev. 2016; 272(1): 97–108.
  17. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264): 1079–1084.
  18. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015; 350(6264): 1084–1089.
  19. Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017; 28(6): 1368–1379.
  20. Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018; 359(6371): 91–97.
  21. Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018; 359(6371): 104–108.
  22. Argilés JM, Busquets S, Stemmler B, et al. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014; 14(11): 754–762.
  23. Flint TR, Janowitz T, Connell CM, et al. Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metab. 2016; 24(5): 672–684.
  24. Turner DC, Kondic AG, Anderson KM, et al. Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res. 2018; 24(23): 5841–5849.
  25. Ryman JT, Meibohm B. Pharmacokinetics of Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol. 2017; 6(9): 576–588.
  26. Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017; 36(1): 11–48.
  27. Motzer RJ, Escudier B, McDermott DF, et al. CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19): 1803–1813.
  28. Sharma P, Tykodi SS, Escudier B, et al. “Three-year efficacy and safety update from the phase III checkmate 025 study of nivolumab (NIVO) v everolimus (EVE) in patients with advanced renal cell carcinoma (aRCC), ” Oncol. Res. Treat., 2018, vol. 41 (Supple, p. : 78P.
  29. Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 investigators. CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol. 2017; 72(6): 962–971.
  30. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2): 115–124.
  31. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8): 722–731.
  32. Xu C, Chen YP, Du XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018; 363: k4226.
  33. Chapman PB, Liu NJ, Zhou Q, et al. Time to publication of oncology trials and why some trials are never published. PLoS One. 2017; 12(9): e0184025.
  34. Motzer R, Tannir N, McDermott D, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 2018; 378(14): 1277–1290.
  35. Amin A, Plimack ER, Ernstoff MS, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018; 6(1): 109.
  36. Ferguson TA, Choi J, Green DR. Armed response: how dying cells influence T-cell functions. Immunol Rev. 2011; 241(1): 77–88.
  37. Lanitis E, Dangaj D, Irving M, et al. Mechanisms regulating T-cell infiltration and activity in solid tumors. Ann Oncol. 2017; 28(suppl_12): xii18–xii32.
  38. Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018; 29(6): 1437–1444.
  39. Thompson J, Szabo A, Arce-Lara C, et al. P1.07-008 Microbiome & Immunotherapy: Antibiotic Use Is Associated with Inferior Survival for Lung Cancer Patients Receiving PD-1 Inhibitors. Journal of Thoracic Oncology. 2017; 12(11): S1998.
  40. Huemer F, Rinnerthaler G, Westphal T, et al. Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. Oncotarget. 2018; 9(23): 16512–16520.
  41. Tinsley N, Zhou C, Villa S, et al. Cumulative antibiotic use and efficacy of immune checkpoint inhibitors in patients with advanced cancer. Journal of Clinical Oncology. 2018; 36(15_suppl): 3010–3010.
  42. Motzer R, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. The Lancet Oncology. 2013; 14(6): 552–562.
  43. Choueiri T, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. The Lancet Oncology. 2016; 17(7): 917–927.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl